WASHINGTON - Pfizer’s coronavirus vaccine offers strong protection after the first dose, the F.D.A. said in its first analysis of the clinical trial data.
Last month, Pfizer and BioNTech announced that their two-dose vaccine had an efficacy rate of 95 percent after two doses administered three weeks apart.
The new analyses show that the protection starts kicking in far earlier.
Furthermore, the vaccine worked well regardless of a volunteer’s race, weight or age.
